The national contract covers FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne RNA, and FoundationOne Heme.

The tool uses two blood-based biomarkers and up to five clinical features to generate a risk score for prostate cancer aggressiveness.

Less than one quarter of pathology labs have adopted whole-slide imaging so far, but pathologists and companies in the space are optimistic of continued growth.

The change applies to qualitative and quantitative hepatitis B virus antigen, antibody, and nucleic acid assays that are used to detect acute and chronic infections.

The agreement includes $650 million of 4.35 percent senior notes, $500 million of 4.55 percent senior notes, and $850 million of 4.8 percent senior notes.

Several firms are bringing high-sensitivity cardiac troponin testing into the ER, although doctors are not yet certain how ...

The letter encourages drug developers to "further study and use" αSyn-SAA testing for selecting patients for clinical trials for Parkinson's and related diseases.

The Baltimore-based subsidiary of Japan's Sysmex said that the test is used to identify genetic mutations that are relevant for the treatment of various cancer types.

NEW YORK – A group of researchers from the University of North Carolina, Chapel Hill have validated an array-based assay for subtyping pancreatic cancer that they believe may help determine which ...

Last week, readers were most interested in a story about how diagnostic firms may be impacted by the FDA's final rule on laboratory-developed tests.

Quest will become the exclusive independent national laboratory provider of clinical lab and anatomic pathology services for Sentara members in Florida and Virginia.

The drop represents a return to a more normal pace of openings post-pandemic but likely also reflects the reimbursement and regulatory challenges facing the industry.